Navigation Search

Cancer Clinical Trials


Every day, Maimonides Cancer Center brings patients leading-edge treatments, right here in Brooklyn.

While participating in a clinical trial is not for everyone, there may be potential benefits, such as providing an alternative method of care, and you may help researchers answer important questions about promising new treatments, which could lead to advances in the way cancer is treated in the future.

Choosing to participate in a clinical trial is an important personal decision. Our goal is to provide information to help you decide whether or not to take part in a cancer research trial. Patients must meet certain requirements to participate in clinical trials.

For information about participating in a cancer clinical trial, please contact:

Laura Covolus, RN BS
Research Nurse Coordinator
Bina Valenzano

Open Clinical Trials for Cancer at Maimonides



Bladder Cancer


A Phase III Randomized Adjuvant Study of MK-3475 ( Pembrolizumab) In Muscle Invasive and Locally Advanced Urothelial Carcinoma ( AMBASSADOR).

Breast Cancer  

NSABP B-51 - Phase III

Aim: To study women who have cancer cells in the lymph nodes at the time that the breast cancer is diagnosed and have chemotherapy before surgery that clears the cancer cells from the lymph nodes.

This study asks 1) if, after lumpectomy, radiation to the breast and lymph nodes will be better than radiation only to the breast at keeping breast cancer from returning, and 2) if, after mastectomy, radiation to the area where the breast used to be and to the lymph nodes is better than no radiation at keeping breast cancer from returning. 

This study also asks whether giving radiation as described above will help women live longer.

 Rectal Cancer    

N1048 - Phase II/III

Aim: To see if radiation can be avoided for a select group of rectal cancer patients who have a good response to 6 treatments with a chemotherapy combination regimen known as FOLFOX.

Lung Cancer

Alliance 151216 (ALCHEMIST)

Aim: To examine lung cancer patients’ surgically removed tumors for certain genetic changes, and possibly refer there patients to a treatment study (below) with drugs that may specifically target tumors that have these genetic changes.

Lung Cancer

Alliance 081105 - Phase III


Aim: To compare any good and bad effects patients may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug), which targets the EGFR mutation.    

Lung Cancer

E4512 - Phase III

Aim: To compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI®), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer.

Lung Cancer

EA5142 - Phase III

Aim: To find if adding the study drug, Nivolumab (also known as OPDIVO®), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer.

Pancreatic Cancer  

RTOG 0848 - Phase III

Aim: To see if a drug (Erlotinib) along with
chemoradiation can improve outcome for patients with pancreatic cancer.

ALL Cancer Diagnosis

CAM study

Aim: To study/catalog the types of complementary (alternative) medicine (“CAM”) among patients at Maimonides, in an effort to increase understanding and possibly establish a CAM program at Maimonides.